Global Gene Panel Market to Reach USD 13,114.95 Million by 2032 | CAGR of 17.7%
Category : Pharmaceuticals | Published Date : Jan 2025 | Type : Press Release
Gene Panel Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Gene Panel Market was valued at USD 3,560.85 million in 2024 and is projected to grow at a CAGR of 17.7%, reaching USD 13,114.95 million by 2032. Gene panels are advanced diagnostic tools used to analyze multiple genes simultaneously to detect genetic mutations linked to diseases or traits. These panels leverage next-generation sequencing technologies to deliver accurate and efficient diagnostic results, enhancing healthcare outcomes through precision medicine.
The report comprises the Gene Panel Market Share, Size & Industry Analysis, based on Product & Service (Test Kits & Reagents, Services), Technique (Amplicon-Based Targeted Sequencing, Hybridization-Based Targeted Sequencing), Design (Predesigned Gene Panels, Customized Gene Panels), Application (Cancer Risk Assessment, Pharmacogenetics, Diagnosis of Congenital Disorders, Others), End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies), and Region (North America, Europe, Asia-Pacific, Middle East & Africa, Latin America), and Forecast, 2025-2032.
The report contains detailed information on Gene Panel Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Increasing adoption of gene panels for cancer diagnostics and advancements in genetic testing techniques drive market growth, while the high cost of testing remains a challenge.
Segmental Analysis :
Based on product & service, the market is segmented into Test Kits & Reagents and Services.
- The test kits & reagents segment accounted for the largest share in 2023, driven by their widespread adoption in genetic diagnostics and personalized medicine. Pre-configured gene panels and reagents enhance ease of testing and provide reliable results.
- The services segment is expected to grow at the fastest rate, supported by the increasing demand for customized genetic testing solutions in oncology, hereditary disorders, and pharmacogenomics.
Based on technique, the market is segmented into Amplicon-Based Targeted Sequencing and Hybridization-Based Targeted Sequencing.
- The amplicon-based targeted sequencing segment dominated the market in 2023 due to its cost-effectiveness, flexibility, and efficiency in focusing on specific genetic regions, making it ideal for cancer genomics and pharmacogenetics.
- The hybridization-based targeted sequencing segment is projected to grow at the fastest rate, fueled by advancements in probe design and its utility in detecting a wide spectrum of genetic mutations.
Based on design, the market is segmented into Predesigned Gene Panels and Customized Gene Panels.
- The predesigned gene panels segment held the largest share in 2023, attributed to their convenience, broad applicability, and proven reliability in clinical settings for diseases such as cancer and inherited disorders.
- The customized gene panels segment is expected to grow at the fastest CAGR, driven by the growing need for tailored genetic assessments in precision medicine and cancer research.
Based on application, the market is segmented into Cancer Risk Assessment, Pharmacogenetics, Diagnosis of Congenital Disorders, and Others.
- The cancer risk assessment segment accounted for the largest revenue share of 46.50% in 2023, supported by increasing awareness of genetic testing for early cancer detection and tailored treatment strategies.
- The pharmacogenetics segment is anticipated to grow at the fastest rate, driven by the rising emphasis on personalized medicine and tailored drug treatments.
Based on end-user, the market is segmented into Hospitals & Diagnostic Laboratories, Academic & Research Institutions, and Pharmaceutical & Biotechnology Companies.
- The hospitals & diagnostic laboratories segment dominated the market in 2023, attributed to advancements in genomic technologies and the increasing integration of genetic diagnostics in clinical care.
- The pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR, fueled by the integration of gene panels in drug development, clinical trials, and therapeutic applications.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America: Accounted for the largest share in 2024, valued at USD 1,181.16 million, driven by strong healthcare infrastructure, research funding, and increasing adoption of genetic testing technologies.
- Asia-Pacific: Expected to grow at the fastest CAGR of 18.2%, supported by rising healthcare investments, increasing prevalence of genetic disorders, and advancements in biotechnology in China, Japan, and India.
| Report Attributes | Report Details |
| Study Timeline | 2019-2032 |
| Market Size in 2032 | USD 13,114.95 Million |
| CAGR (2025-2032) | 17.7% |
| Product & Service | Test Kits & Reagents, Services |
| Technique | Amplicon-Based Targeted Sequencing, Hybridization-Based Targeted Sequencing |
| Design | Predesigned Gene Panels, Customized Gene Panels |
| Application | Cancer Risk Assessment, Pharmacogenetics, Diagnosis of Congenital Disorders, Others |
| End-User | Hospitals & Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Gene Panel Industry:
- Thermo Fisher Scientific Inc. (United States)
- Illumina, Inc. (United States)
- Agilent Technologies Inc. (United States)
- QIAGEN N.V. (Germany)
- Myriad Genetics, Inc. (United States)
- Foundation Medicine, Inc. (United States)
- Bio-Rad Laboratories, Inc. (United States)
- PerkinElmer Inc. (United States)
- Oxford Nanopore Technologies (United Kingdom)
- MedGenome Labs Pvt. Ltd. (India)
Recent Industry Developments :
- June 2024: Illumina, Inc. launched its next-generation sequencing platform designed for faster and more cost-effective gene panel analysis, targeting oncology and rare genetic disorders.
